[CAS NO. 179386-44-8] Sumanirolemaleate
PRODUCTS SPECIFICATIONS [179386-44-8]
DESCRIPTION [179386-44-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 319.31 |
| Molecular Formula | C15H17N3O5 |
| SMILES | O=C1NC2=C3N1C[C@H](NC)CC3=CC=C2.O=C(/C=C\C(O)=O)O |
1 Publications Citing Use of MCE
Summary
Sumanirole maleate (U-95666E; PNU-95666E) is a highly selective D2 receptor full agonist with an ED 50 of about 46 nM. Sumanirole was developed for the treatment of Parkinson's disease and restless leg syndrome.
IC50 & Target
EC50: 46 nM (D2 receptor)
In Vitro
Sumanirole is a highly valuable tool compound for basic research to identify neurobiological mechanisms that are based on a dopamine D2-linked (vs. D1, D3, D4, and D5-linked) mechanism of action.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00058838 | Pfizer |
Parkinson Disease
|
April 2003 | Phase 3 |
| NCT00036218 | Pfizer |
Parkinson Disease
|
December 2001 | Phase 3 |
| NCT00036205 | Pfizer |
Parkinson Disease
|
August 2000 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 50 mg/mL ( 156.59 mM ; Need ultrasonic)
H 2 O : 10 mg/mL ( 31.32 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.1318 mL | 15.6588 mL | 31.3175 mL |
| 5 mM | 0.6264 mL | 3.1318 mL | 6.2635 mL |
| 10 mM | 0.3132 mL | 1.5659 mL | 3.1318 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (156.59 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.83 mM); Clear solution
